Mangoceuticals, Inc. (MGRX)

NCM – Real Time Price. Currency in USD

0.35

-0.07 (-17.84%)

At close: May 12, 2026, 4:00 PM EDT

0.37

+0.02 (7.09%)

Pre-market: May 13, 2026, 4:29 AM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

Mangoceuticals, Inc. (MGRX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Mangoceuticals, Inc. (MGRX)

Mangoceuticals Stock Doubles After Texas Lawsuit

Mangoceuticals Announces Lawsuit Seeking Damages Exceeding $73 Million Against Former Technology Consulting and Software Development Firm, Clarity Ventures, Inc.

Mangoceuticals, Inc. Announces PCT Patent Filing for MGX-0024 Antiviral Technology to Include Inhibiting Respiratory or Orally Acquired Virus Infection in Animals or Birds

Mangoceuticals' Patented MGX-0024 Achieves Zero Respiratory-Related Mortality in 29,000-Bird Field Trials and Demonstrates Prophylactic Benefit Against H5N1 in Controlled Government Study

Mangoceuticals Stock Skyrockets 50% Friday: What's Driving The Rally?

Mangoceuticals Stock Surges On Early Success Of Subscription TRT Model

MangoRx Experiences Initial Success with Newly Launched $99/month All-Inclusive Injectable Testosterone Replacement Therapy (TRT) Treatment Program

Videos

No Data

Press releases

Mangoceuticals Announces Lawsuit Seeking Damages Exceeding $73 Million Against Former Technology Consulting and Software Development Firm, Clarity Ventures, Inc.

Mangoceuticals, Inc. Announces PCT Patent Filing for MGX-0024 Antiviral Technology to Include Inhibiting Respiratory or Orally Acquired Virus Infection in Animals or Birds

Mangoceuticals' Patented MGX-0024 Achieves Zero Respiratory-Related Mortality in 29,000-Bird Field Trials and Demonstrates Prophylactic Benefit Against H5N1 in Controlled Government Study

MangoRx Experiences Initial Success with Newly Launched $99/month All-Inclusive Injectable Testosterone Replacement Therapy (TRT) Treatment Program

Search stocks

Mangoceuticals, Inc. (MGRX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Mangoceuticals, Inc. (MGRX)

Mangoceuticals Stock Doubles After Texas Lawsuit

Mangoceuticals Announces Lawsuit Seeking Damages Exceeding $73 Million Against Former Technology Consulting and Software Development Firm, Clarity Ventures, Inc.

Mangoceuticals, Inc. Announces PCT Patent Filing for MGX-0024 Antiviral Technology to Include Inhibiting Respiratory or Orally Acquired Virus Infection in Animals or Birds

Mangoceuticals' Patented MGX-0024 Achieves Zero Respiratory-Related Mortality in 29,000-Bird Field Trials and Demonstrates Prophylactic Benefit Against H5N1 in Controlled Government Study

Mangoceuticals Stock Skyrockets 50% Friday: What's Driving The Rally?

Mangoceuticals Stock Surges On Early Success Of Subscription TRT Model

MangoRx Experiences Initial Success with Newly Launched $99/month All-Inclusive Injectable Testosterone Replacement Therapy (TRT) Treatment Program

Videos

No Data

Press releases

Mangoceuticals Announces Lawsuit Seeking Damages Exceeding $73 Million Against Former Technology Consulting and Software Development Firm, Clarity Ventures, Inc.

Mangoceuticals, Inc. Announces PCT Patent Filing for MGX-0024 Antiviral Technology to Include Inhibiting Respiratory or Orally Acquired Virus Infection in Animals or Birds

Mangoceuticals' Patented MGX-0024 Achieves Zero Respiratory-Related Mortality in 29,000-Bird Field Trials and Demonstrates Prophylactic Benefit Against H5N1 in Controlled Government Study

MangoRx Experiences Initial Success with Newly Launched $99/month All-Inclusive Injectable Testosterone Replacement Therapy (TRT) Treatment Program